212 results about "Phosphatine" patented technology

The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular molecular entities by tagging such cells or noncellular molecular entities with a marker that targets the cells or noncellular molecular entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagcytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

Provided are compounds according to Formula (I):

or stereoisomer, prodrug, polymorph, or pharmaceutically acceptable salt forms thereof, wherein X, Y, R¹, R⁶, R⁷, and R⁸ are as defined, and which compounds are effective inhibitors of PI3-kinase and/or other medically and clinically relevant kinases. Also provided are pharmaceutical compositions and methods of using the compounds and compositions as PI3-kinase and kinase inhibitors. More particularly, the compounds of the invention provide treatments and therapeutics for human diseases regulated by, or associated with, the activity of, PI3-kinases and/or protein kinases, or mutant or variant forms thereof.

The invention discloses a metabonomics-based diagnosis marker for chronic obstructive pulmonary disease and application thereof. The diagnosis marker comprises the following 28 blood plasma metabolismmarkers: phosphatidylcholine PC 16:1-36:3, phosphatidylcholine PC 26:0-22:4, phosphatidylcholine PC 26:0-22:3, phosphatidylcholine PC 47:5e, phosphatidylcholine PC 44:11e, phosphatidylcholine PC 16:0-24:5, phosphatidylcholine PC 20:2-20:3, phosphatidylcholine PC 40:10, phosphatidylcholine PC 38:9e, phosphatidylcholine PC 18:1-20:4, phosphatidylcholine PC 16:0-20:3, phenylacetaldehyde, dihydrouracil, nicotinamide, 4-methoxycinnamic acid, ketovaline, threonine, DL-3-aminoisobutyric acid, pyruvic acid, stachyose, caffeic acid, N, N-dimethylaniline, maltotriose, D(-)-gulonate-gamma-lactone, and L-asparaginase. The marker provided by the invention has good classification on metabolome data of patients suffering chronic obstructive pulmonary disease and healthy people, and can accurately distinguish the patients suffering chronic obstructive pulmonary disease from the healthy people.

The disclosure provides compositions treating traumatic brain injuries such as concussions. In one embodiment, the composition comprises phosphatidylserine, phosphatidylcholine, quercetin, astaxanthin, R-alpha lipoic acid, N-acetyl cysteine, taurine, L-glutamine, carnitine, D-ribose, creatine, epigallocatechin gallate, melatonin, ginkgo leaf extract, curcumin and L-glycine. The disclosure also provides methods for treating traumatic brain injuries such as concussions by administering an effective amount of the compositions described within.

The invention discloses a metabonomics-based application of endogenous small-molecular substances in rapid detection of hepatotoxicity. The endogenous small-molecular substances are 12 hepatotoxicity biomarkers, i.e., L-alanine, L-phenylalanine, L-carnitine, L-carnitine palmitoyl, tryptophan, arachidonate, cholic acid, lysophosphatidylcholine (14:0), lysophosphatidylcholine (16:1), lysophosphatidylcholine (18:2), lysophosphatidylcholine (20: 3) and hemolysis phosphatidyl ethanolamine (18:2); and the endogenous small-molecular substances also refers to 3 special hepatotoxicity biomarkers, i.e. L-carnitine, cholic acid and lysophosphatidylcholine (14:0). By adopting the hepatotoxicity biomarkers, the discovery and diagnosis of the liver injury can be earlier than those of the existing biochemical detection indexes, the hepatotoxicity biomarkers can be well used for preventing, discovering and treating the hepatotoxicity, the limitation of the existing indexes can be overcome, and accurate detection information can be provided in time.

The present invention provides methods for identifying agents that increase lifespan and increase resistance to oxidative and/or electrophilic stress. Also provided are methods for identifying biomarkers of longevity or identifying pathways governing longevity in response to phosphatidylinositol 3,4,5-triphosphate signaling.

The invention relates to a high-performance liquid chromatography of phosphatidylserine. The High-performance liquid chromatography comprises the steps of (1) preparing a phosphatidylserine standard solution, and using a chloroform-methanol solution to dissolve and fix the constant volume to be 80 to 400ug/ml; (2) preparing a phosphatidylserine sample solution, using the chloroform-methanol solution to dissolve and fix the volume, and diluting and preparing the sample solution of which the phosphatidylserine content is within the concentration range of standard serial solutions; (3) measuring the standard solution and the sample solution under the condition that the high-performance liquid chromatography cooperates with an evaporative light-scattering detector, performing logarithmetics on the peak area of the standard solution as a y-coordinate, performing logarithmetics on the concentration of the standard solution as an x-coordinate, drawing a double logarithmic standard curve, and finding the concentration of the sample solution from the double logarithmic standard curve according to the peak area. The high-performance liquid chromatography has the following beneficial effects: due to the fact that the high-performance liquid chromatography cooperates with the evaporative light-scattering detector, a simple and effective method is provided for the quality control during a phosphatidylserine production process through the entering of different mobile phase volume ratios.

The invention discloses a receipt of gypenoside lipidosome consisting of sterol. The receipt comprises gypenoside, a phosphatide material and the sterol. The invention further discloses a preparation method of the gypenoside lipidosome consisting of the sterol. A preparation form of the lipidosome can be a freeze-drying injection, an injection, a transdermal preparation, aerosol, oral liquid, a solution, an eye-drops preparation, a tablet or a capsule. The gypenoside lipidosome has important treatment effects for hyperlipidemia and cardiovascular and cerebrovascular diseases, and furthermore, has positive treatment and prevention effects for tumor, hepatitis, gastritis, gastric and duodenal ulcer, gastroptosis, stomatitis, diabetes mellitus, astriction, haemorrhoids, asthma, cephalagra, acne, stain, gall-stone, numbness of limbs, pachulosis, male infertility, recession of sexual functions, fatness, white hair and baldness. Furthermore, the physical strength of a human body can be enhanced, the immunity of the organism is improved, the state of fatigue can be relieved, the sleep quality can be obviously improved, the appetite can be whetted, and the senescence can be delayed.

The invention discloses a complete humanized antibody which is selected from humanized high-capacity phage antibody library and is high-affinity-combined with phosphatidylinositol proteoglycan 3. The invention includes a selection method of the antibody, an antibody coding sequence and corresponding amino acid residue sequence, and especially includes three CDR-zone sequences respectively at a heavy chain and a light chain, combination characters of an antigen and the construction method of the complete antibody. The antibody is a complete humanized antibody, is used for treatment in human body, is low in immunogenicity, is less in toxic and side effects, and has a potential value of treating liver cancer and melanin tumor.

The invention relates to a SN38 lipid composition, and a preparation method and application thereof. The SN38 lipid composition comprises SN38, phosphatide, oil for injection, cholesterol, a long-circulating film material, a functional material capable of forming a protection layer on the surface of lipid, and a functional adjuvant capable of reversing drug resistance. The SN38 lipid composition overcomes the problems that drugs are poor in solubility and hard to prepare preparations, that conventional lipid preparations are low in entrapment rate and poor in in-vitro stability, that drugs areprone to rapid leakage and the like in the prior art; and the SN38 lipid composition improves the in-vivo circulation time of drugs, has a certain targeting function, allows drugs to be enriched at tumor sites, reduces toxic and side effect, substantially enhances drug effect, and can overcome the multidrug resistance of tumors to a certain degree.

A yolk lecithin capsule is prepared from yolk lecithin 100 (wt. portions), vegetative oil 100-150, VE3, and tert-butylhydroquinone 0.03 as antioxidizing agent. Its advantages are no need of cold-chain transportation, and high content of phosphatidylcholine and linolenic acid.

The invention relates to a lipid gel medicinal preparation, a preparation method and a purpose. The lipid gel medicinal preparation comprises PEGylated phosphatide, non-PEGylated phosphatide, an active substance with effective treatment amount and a solvent, wherein the solvent contains water or physiological aqueous medium. The preparation method comprises the following steps: i) preparing an active substance solution; ii) mixing the above active substance solution with PEGylated phosphatide, non-PEGylated phosphatide, the solvent and other pharmaceutically acceptable accessory with a prescription amount; and iii) heating and mixing a solution obtained in the step ii), and fully swelling. The invention also comprises an application of the lipid gel in a slow release drug delivery system. The preparation has high maximum drug loading, is suitable for large scale production, and has the advantages of simple preparation method, low toxicity and obvious slow release effect.

The invention discloses a breast cancer-related kinase mutation detection panel. The detection panel comprises receptor tyrosine kinase (RTK), phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK) related genes, and an exon region and a part of intronic regions of a downstream gene. The invention further discloses a kit containing the detection panel. The detection panel can detect gene mutation guiding diagnosis and treatment more efficiently, is of great significance to clinical diagnosis and discovery of a target spot of target treatment, and can help lower gene detection cost of patients.

The invention discloses phosphatidylserine pressed candy and a production process thereof. The phosphatidylserine pressed candy is prepared from raw materials in parts by weight as follows: 285-315 parts of phosphatidylserine, 185-215 parts of soybean lecithin, 3-7 parts of hydroxypropyl methylcellulose, 460-480 parts of isomaltitol, 8-12 parts of silicon dioxide and 9-21 parts of magnesium stearate through pre-treatment, weighing, mixing, granulation, drying, pressing and packaging processes. The phosphatidylserine pressed candy has the advantages that the efficacy of improving nerve cells, improving memory and the like can be realized through scientific matching and the synergetic function of multiple raw materials, and the candy is safe, has no side effects, is convenient to eat and has better market application prospect.

A multilocular liposome of mitomycin for preventing and treating tumor is prepared through dissolving the lipoid component (neutral phosphatide, cholesterol and neutral lipid) in organic solvent, dissolving mitomycin in buffering salt solution, mixing, emulsifying to obtain water-in-oil primary emulsion, adding external water phase containing isotonic regulator, stirring to become water-in-oil-in-water emulsion, and removing organic solvent.

A self-assembled precursor liposome of camptothecine contained medicine is proportionally prepared from camptothecine contained medicine, phosphatide, polyethylene glycol and dispersing medium through mixing, dispersing, press filtering by millipore film, and pouring it in a container full of N2.

The invention provides an alprostadil injection. Every 1000ml of alprostadil injection comprises the following raw materials: 5mg of alprostadil, 90-110g of soybean oil, 15-20g of phosphatide, 2-3g of oleic acid, 22.1-25g of isoosmotic agent, and appropriate pH modifier, wherein the content of the pH modifier is enough to regulate the pH of the injection to be 5.0-6.0. The invention also provides a preparation method for the alprostadil injection. Compared with the prior art, the alprostadil injection prepared by the method has higher encapsulation efficiency and content of main drug, contains fewer related substances, has good stability, and provides safety guarantee for clinical medication.

The invention provides a serum metabolism marker for diagnosis of gestational diabetes mellitus and application thereof. Specifically, phosphatidyl ethanolamine PE (O-22: 6_2: 0) and phosphatidyl ethanolamine PE (O-22: 6_3: 0) can be used as a biomarker of gestational diabetes mellitus and can be used for evaluating the illness risk of gestational diabetes mellitus or diagnosing gestational diabetes mellitus. The serum metabolism marker has the advantages of high accuracy and high sensitivity, thereby having important clinical application value.

This invention relates to compositions containing combinations of a balanced phosphatidylcholine composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from an imbalance of fatty acids and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.

The invention discloses a vitamin K composition, and a preparation method, a preparation and applications thereof. The vitamin K composition contains a carrier material and a solid accessory ingredient besides the carrier material; the carrier material is loaded with vitamin K, a cholic acid compound, a phosphatide, a cosurfactant, and a random selected oil through adsorption; the vitamin K composition is capable of realizing self emulsifying in an aqueous solution with a pH value ranging from 1.0 to 8.0 so as to obtain a stable nanometer emulsion; the in vitro dissolving out and in vivo bioavailability of vitamin K are increased obviously; the vitamin K composition is a solid composition, so that defects of liquid preparations in stability and using convenience are avoided; and the vitamin K composition is suitable for patients with bile duct obstruction.